

9 September 2008

Proposal to list Duolin HFA (salbutamol with ipratropium) aerosol inhaler

Summary

PHARMAC and Rex Medical Limited have signed a provisional agreement for the supply of a new brand of salbutamol with ipratropium aerosol inhaler, Duolin HFA. The agreement would result in this product being subsidised only if it attains registration by Medsafe. This proposal would not affect the listing of the current brand of this product, Combivent.

Proposal

If Duolin HFA attains registration by Medsafe, it would be listed in Section B of the Pharmaceutical Schedule at the following price and subsidy:

Chemical and strength	Presentation	Pack size	Proposed price and subsidy
Salbutamol 100 µg with 20 µg ipratropium	Aerosol inhaler, CFC-free	200 doses OP	\$12.19

Duolin HFA would be protected from delisting until 1 July 2013, and from subsidy reduction until 1 July 2012.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback please submit it in writing by 4 pm on **Friday 26 September 2008** to:

Sean Dougherty
Therapeutic Group Manager
PHARMAC
PO Box 10 254
Wellington 6143

Email: sean.dougherty@pharmac.govt.nz

Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.